Skip to main content
TipRanks
Go Ultimate75% OFF

Draegerwerk AG & Co. KGaA (DRW8) AI Stock Analysis

2 Followers
DE:DRW8

Draegerwerk AG & Co. KGaA

(XETRA:DRW8)

Select Model
Rating:70Outperform
Price Target:EUR 98.00â–²(10.11% Upside)
Action:upgraded
Date:10/31/26

Dräger scores well on fundamentals and valuation. The standout strength is an exceptionally conservative balance sheet — low debt, rising equity and over half of assets equity-funded — combined with three years of margin repair and a sharp rebound in cash flow. At a P/E of 11.2 with a near 3% dividend yield, the shares look inexpensive, and the latest earnings call confirmed guidance while highlighting improving order intake, a stronger Safety division, defence growth potential and the removal of the FDA warning letter. The main offsets are weak near-term technicals — the price sits below its 20-, 50- and 100-day averages with a negative MACD — alongside structurally thin margins, a still loss-making Medical division, rising functional expenses and soft demand in China and the Americas.

Positive Factors
Safety division growthSafety is showing broad operating momentum across product areas and regions, with double-digit order growth and an EBIT margin above 11%. This strengthens Dräger’s earnings base and provides a durable counterweight to weakness in Medical over the next several quarters.
Negative Factors
Medical remains loss-makingMedical has improved year over year but still consumes earnings rather than contributing positively, and its third-quarter EBIT also declined. Continued losses in a major segment could limit group margin expansion and require sustained execution on product mix, efficiency, and commercial recovery.

Draegerwerk AG & Co. KGaA (DRW8) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%60%DE:DRW8+49.03%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.59B
Dividend Yield
2.48%
Average Volume (3M)
4,046
Price to Earnings (P/E)
12.8
Beta (1Y)
0.67
Revenue Growth
5.06%
EPS Growth
40.18%
Country
Germany
Employees
16,687
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Draegerwerk AG & Co. KGaA Business Overview & Revenue Model

Company Description

Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the heal...

How the Company Makes Money

Dräger generates revenue primarily through the sale of equipment, consumables/accessories tied to its installed base, and recurring service and maintenance offerings across its Medical and Safety segments. 1) Product/equipment sales (often higher-tic...

Draegerwerk AG & Co. KGaA Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:15.58%|Next Earnings Date:Apr 30, 2025
Earnings Call SentimentPositive

The call was predominantly positive. Dräger reported strong nine-month order intake, sales, earnings, cash flow, balance-sheet improvement and Safety division momentum, confirmed full-year guidance, and highlighted the lifting of the FDA warning letter and opportunities in defense. These positives were tempered by third-quarter EBIT and Medical performance declines, higher functional expenses, a negative net tariff effect, weaker China demand, Americas and APAC pressure in specific areas, and the need for tight fourth-quarter cost management.

Positive Updates

Strong Nine-Month Top-Line and Earnings Growth
Order intake was around EUR 2.7 billion and noticeably above the high prior-year level. Net sales grew by around EUR 110 million to around EUR 2.5 billion, while earnings rose by roughly EUR 35 million to around EUR 112 million. The EBIT margin increased to 4.6%.

Negative Updates

Americas Order Intake Decline
Group order intake growth was supported by all regions except the Americas, which saw a significant decline as a result of a major hospital infrastructure systems order from Mexico in the second quarter of 2025.

Company Guidance

For the full year of 2026, Dräger confirmed guidance for net sales growth of 2% to 6%, net of currency effects, and an EBIT margin of 6% to 8%; the target remains unchanged to keep full year expense growth below net sales growth, free cash flow is expected to continue to develop positively, and the company expects order intake and sales to be better for the remainder of the year, with the fourth quarter being the best quarter. The goal to increase defense business from roughly EUR 100 million, which was had in around '25, to around EUR 300 million is unchanged, and the dividend policy remains unchanged at distributing at least 30% of net income as dividend.

Draegerwerk AG & Co. KGaA Financial Statement Overview

Summary

Dräger combines a fortress balance sheet (Score 82) with improving cash generation (Score 74) and a steady earnings recovery (Score 68). Debt has fallen to €228.9 million against €1.71 billion of equity (debt/equity of 0.23), equity funds roughly 52% of assets, operating cash flow reached €320.5 million TTM and free cash flow €227.4 million. Margins have expanded consistently — gross margin to 46.0%, operating margin to 7.7% and net margin to 4.8% — lifting net income to €169.6 million. Offsetting this are structurally thin profitability for a medical device business, low-single-digit revenue growth, moderate 10.6% return on equity, and a track record of volatility, including the 2022 loss year and negative free cash flow.

Income Statement

68Positive

Balance Sheet

82Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.59B3.48B3.37B3.37B3.05B3.33B
Gross Profit1.67B1.52B1.51B1.46B1.24B1.54B
EBITDA404.63M384.83M351.68M318.33M62.63M421.65M
Net Income169.59M139.50M124.41M110.43M-64.56M154.23M
Balance Sheet
Total Assets3.26B3.28B3.09B3.09B3.11B3.18B
Cash, Cash Equivalents and Short-Term Investments270.90M284.06M248.18M279.36M319.50M577.38M
Total Debt228.93M405.11M395.58M471.38M361.95M348.01M
Total Liabilities1.55B1.65B1.56B1.69B1.79B1.92B
Stockholders Equity1.71B1.63B1.54B1.41B1.32B1.26B
Cash Flow
Free Cash Flow227.35M166.50M103.52M121.47M-231.09M274.54M
Operating Cash Flow320.54M238.33M167.31M189.68M-144.23M384.89M
Investing Cash Flow-82.54M-98.15M-43.39M-67.34M36.83M-109.92M
Financing Cash Flow-162.12M-83.99M-161.38M-154.56M-29.38M-334.64M

Draegerwerk AG & Co. KGaA Technical Analysis

Technical Analysis SentimentPositive
Last Price89.00

Price Trends

50DMA82.95Positive
100DMA81.27Positive
200DMA75.57Positive

Market Momentum

MACD1.17Negative
RSI66.30Neutral
STOCH82.14Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW8, the sentiment is Positive. The current price of 89.00 is above the 20-day moving average (MA) of 78.32, above the 50-day MA of 82.95, and above the 200-day MA of 75.57, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 66.30 is Neutral, neither overbought nor oversold. The STOCH value of 82.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DRW8.

Draegerwerk AG & Co. KGaA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:DRW8 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:EUZDE:EUZ80OutperformEUR 922.97M16.9520.26%1.49%4.05%36.66%
DE:SHLDE:SHL77OutperformEUR 48.89B22.1311.72%2.28%1.09%3.52%
DE:AFXDE:AFX73OutperformEUR 2.89B19.325.52%1.70%-0.06%-38.81%
DE:DRW8DE:DRW870OutperformEUR 1.90B12.8310.20%2.48%5.06%40.18%
DE:M3VDE:M3V55NeutralEUR 38.95M28.167.77%4.44%-6.92%-67.82%
DE:SBSDE:SBS54NeutralEUR 347.66M-8.19-18.69%2.10%――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%DE:DRW8DE:AFXDE:EUZDE:M3VDE:SBSDE:SHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:DRW8 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:DRW8Draegerwerk AG & Co. KGaA (0MT8)89.0030.2551.49%
DE:AFXCarl Zeiss Meditec32.26-10.15-23.93%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik14.75-0.50-3.29%
DE:M3VMeVis Medical Solutions21.40-2.50-10.46%
DE:SBSSTRATEC Biomedical28.609.0846.48%
DE:SHLSiemens Healthineers43.823.037.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026